I welcome the decision by NHS England to approve Everolimus - the life-saving drug to treat brain tumours caused by the ultra-rare disease Tuberous Sclerosis Complex (TSC) - for routine commissioning.
Over the weekend, NHS England announced the results of its re-run annual prioritisation process, which it had to run in order to consider the HIV prevention drug PreEP - https://www.england.nhs.uk/2016/12/hiv-prevention-pregramme/
As part of this, it invited drug manufactures, particularly of treatments that were unsuccessful in the original process, such as Everolimun, to submit revised prices.
In the revised results, I am delighted to say that the decision not to routinely commission Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex was reversed. It will now be routinely commissioned on the NHS in England.
This is something I have been asking the Government to look at and I am thankful to those who brought it to my attention. This is a good result all round.